Mesoblast’s Revascor Therapy Shows Promise in Heart Failure

Mesoblast (MESO) has released an update.

Mesoblast’s allogeneic cell therapy, Revascor, has shown promising results in improving survival and reducing major cardiovascular events in high-risk ischemic heart failure patients with inflammation, according to a recent study. The therapy significantly lowered the risk of cardiovascular death and major adverse cardiovascular events, highlighting its potential as a disease-modifying treatment. This breakthrough could position Mesoblast favorably in the market as they seek approval for broader application of their heart failure product.

For further insights into MESO stock, check out TipRanks’ Stock Analysis page.